Clinical trials: Second Line Treatment
Advanced Small Cell Lung Carcinoma
Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study.
Initial chemosensitivity is known concerning SCLC but relapse is almost systematic, especially at a metastatic stage. Brain metastasis are identified around 40 to 50% during the evolution of the disease.
- Trial name
- EPITAX (NCT06550518)
- Where
- 3 sites in France
- Volunteers
- 29 people
- Sponsor
- University Hospital, Brest
Advanced Renal Cell Carcinoma (aRCC)
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
This study will collect real-world data for the new treatment pathways for all patients with Advanced Renal Cell Carcinoma (ARCC) who were treated with a 1L IO (first-line, Immuno-Oncology checkpoint inhibitor) combination…
- Trial name
- CARINA (NCT04957160)
- Where
- 9 sites in United Kingdom
- Volunteers
- 281 people
- Sponsor
- Ipsen
Locally Advanced or Metastatic Renal Cell Carcinoma
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after…
- Trial name
- CaboPoint (NCT03945773)
- Testing
- Cabozantinib
- Where
- 40 sites in Austria, France and 5 more
- Volunteers
- 127 people
- Sponsor
- Ipsen
Metastatic Colorectal Cancer
Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC
Trial design: Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with "Hyaluronic acid-Irinotecan" or "HA-Irinotecan") regimen. Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve.
- Trial name
- FOLF(HA)iri (NCT01290783)
- Testing
- Irintoecan, HA-Irinotecan solution for Infusion
- Where
- 5 sites in Australia
- Volunteers
- 390 people
- Sponsor
- Alchemia Oncology
B-cell Chronic Lymphocytic Leukemia
A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response
Open label multicenter, two-step, non-randomized (pilot) study to analyze the safety of 4 cycles of 3-day 40mg/m2 oral fludarabine with simultaneous thrice weekly application of 30mg alemtuzumab s.c.
- Trial name
- NCT00565981
- Testing
- Fludarabine phosphate, Alemtuzumab
- Where
- 8 sites in Austria
- Volunteers
- 10 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
ITP - Immune Thrombocytopenia
Immune Markers in Pediatric ITP on Second Line Therapy
Immune thrombocytopenia (ITP) is a common autoimmune disease characterized by low platelet count and increased risk of bleeding.
- Trial name
- NCT06093529
- Testing
- complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ.
- Volunteers
- 42 people
- Sponsor
- Assiut University
Biliary Tract Cancer
Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer
Biliary tract cancer is relatively rare cancer, with generally poor prognosis. In metastatic/recurrent biliary tract cancer, the most commonly used 1st-line chemotherapy is gemcitabine+cisplatin combination.
- Trial name
- NCT02433639
- Testing
- TH-302 monotherapy
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Seoul National University Hospital
Urothelial Carcinoma
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
The purpose of this study is to explore the safety and activity of docetaxel + ASA404 as second-line chemotherapy in patients with advanced urothelial carcinoma.
- Trial name
- NCT01071928
- Testing
- Docetaxel, ASA404
- Sponsor
- Hoosier Cancer Research Network
Hodgkin Lymphoma
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
This is a single-arm, phase II, multi-centre study of the safety and efficacy of the PD-1 inhibitor, nivolumab, as second-line or third-line salvage therapy as a bridge to stem cell transplant (SCT) in relapsed/ refractory…
- Trial name
- ANIMATE (NCT03337919)
- Testing
- Nivolumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- University College, London
Small Cell Lung Cancer
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
This study is an open, single-arm, single-center phase II clinical study, which aims to evaluate the efficacy and safety of adebelizumab combined with irinotecan liposome in the second-line treatment of advanced small cell lung…
- Trial name
- NCT07004712
- Testing
- Adebelizumab combined with irinotecan liposome as second-line therapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University Cancer Hospital & Institute
Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies
SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies
This is a prospective, open-label, multicenter, single-arm Phase II study designed to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT/SKB264) in combination with tagitanlimab (KL-A167) as second-line or later…
- Trial name
- NCT07738757
- Testing
- Sacituzumab Tirumotecan (Sac-TMT), Tagitanlimab
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Phase II Avastin Trial for Stage IIIB/IV NSCLC
This is a randomized, open-label, multicenter study in 160 patients in first line treatment and 114 in second line treatment with advanced or metastatic NSCLC (Stage IIIB/IV).
- Trial name
- NCT00766246
- Testing
- bevacizumab, docetaxel, carboplatin
- Volunteers
- 125 people
- Sponsor
- Pharmatech
Non Small Cell Lung Cancer
Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV
This trial will compare the efficacy of irinotecan/cisplatin and pemetrexed/cisplatin in the second-line treatment of patients with stage IIIB/IV NSCLC
- Trial name
- NCT00614965
- Testing
- Irinotecan, Cisplatin, Pemetrexed
- Where
- 2 sites in Greece
- Volunteers
- 124 people
- Sponsor
- Hellenic Oncology Research Group
Small Cell Lung Cancer, Small Cell Lung Cancer Limited Stage
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
Chemotherapy still constitutes the backbone of small-cell lung cancer (SCLC) therapy, particularly in the extensive disease (ED) stage (ED-SCLC).
- Conditions
- Small Cell Lung Cancer, Small Cell Lung Cancer Limited Stage, Small Cell Lung Cancer Extensive Stage
- Trial name
- NCT03059667
- Testing
- Atezolizumab, Topotecan, Carboplatin
- Where
- 18 sites in France
- Volunteers
- 73 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Colorectal Cancer
c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
The primary endpoint is to evaluate the progression-free survival (PFS).
- Trial name
- NCT04833036
- Testing
- Irinotecan, cetuximab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Colorectal Neoplasms
Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)
Bevacizumab, an antibody against vascular endothelial generated factor (VEGF), combined with the fluorouracil-based chemotherapy regimens has been approved in the 1st and 2nd line treatments for metastatic colorectal…
- Trial name
- BABST-C (NCT03743428)
- Testing
- Apatinib Mesylate Tablets, Bevacizumab Injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen People's Hospital
Advanced Biliary Cancer
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer
This study is a randomized, parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus chemotherapy as second-line treatment in subjects with advanced…
- Trial name
- NCT04809142
- Testing
- TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection
- Where
- 17 sites in China
- Volunteers
- 392 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Acute Severe Ulcerative Colitis
Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）
This clinical trial aims to evaluate the comparative efficacy and safety of upadacitinib versus infliximab as second-line treatments for acute severe ulcerative colitis, addressing the following key questions: (1) Can…
- Trial name
- NCT07550673
- Testing
- upadacitinib, Infliximab
- Where
- 4 sites in China
- Volunteers
- 226 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Advanced Breast Cancer
E3 Breast Cancer Taxotere Combination
To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology
- Trial name
- NCT00494481
- Testing
- Vandetanib (ZD6474), Docetaxel
- Where
- 12 sites in Hungary, South Africa and 3 more
- Volunteers
- 64 people
- Sponsor
- Genzyme, a Sanofi Company
Small Cell Lung Cancer (SCLC)
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
SCLC has short doubling time, high proliferation rate and early widespread metastasis. Most patients with SCLC have hematogenous metastasis. SCLC is highly sensitive to initial chemoradiotherapy, but the recurrence rate is high.
- Trial name
- NCT05027100
- Testing
- Anlotinib Tislelizumab Irinotecan
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Haibo Zhang